TickerGraveyard
TickerGraveyard

HOOK

Taken Private
HOOKIPA Pharma Inc.

HOOK — Post-Mortem

HOOKIPA Pharma Inc. was a clinical-stage biopharmaceutical company focused on immunotherapeutics for infectious diseases like Hepatitis B (HBV) and HIV. Originally incorporated in Austria in 2011, it transitioned to a Delaware corporation in 2017 and engaged in a critical partnership with Gilead Sciences to develop innovative therapies. Following ongoing challenges in achieving commercial viability, the company embarked on a strategic asset sale to Gilead in May 2025. On July 29, 2025, stockholders voted to approve the sale of its essential assets and subsequent dissolution of the company, leading to its liquidation. This marked the conclusion of HOOKIPA's efforts to develop and market its technology platform, which had shown promise but ultimately could not secure sustainable market entry

HOOKIPA Pharma Inc. liquidated after selling key assets to Gilead Sciences and dissolving the company following approval from stockholders, marking the end of its clinical-stage pursuits.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Founded in 2011 as Hookipa Biotech AG, the company shifted to the Delaware corporate structure in 2017, aiming to create immunotherapies for HBV and HIV.

Peak

HOOKIPA's partnership with Gilead in June 2018, which involved financial backing and development collaboration, marked a high point as it positioned the company to leverage Gilead's capabilities.

Turning Point

The company’s decline became evident when trials failed to demonstrate marketable efficacy, leading to operational challenges and a strategic pivot toward asset divestiture in May 2025.

End

Stockholders faced a definitive choice on July 29, 2025, to approve the asset sale and dissolution, leading to the official liquidation of HOOKIPA which ceased all operations.

Impact

The dissolution of HOOKIPA Pharma Inc. illustrates the challenges faced by biotech firms in transitioning from clinical stages to commercial viability, underlining the high stakes in biopharmaceutical development.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Investors should closely monitor clinical trial outcomes and market reactions, as these can precipitate significant company shifts.

  2. 2

    Partnerships with established firms can provide essential resources but also heighten dependency, influencing strategic decisions under duress.

  3. 3

    Involvement in multiple clinical pipelines, while diversifying risk, may also spread resources thin, complicating effective development and commercialization.

Frequently Asked Questions

When was HOOKIPA Pharma Inc. originally founded?
HOOKIPA Pharma Inc. was originally founded in 2011 as Hookipa Biotech AG.
What major decision did stockholders make on July 29, 2025?
On July 29, 2025, stockholders approved the sale of key assets to Gilead Sciences and the subsequent dissolution of HOOKIPA Pharma Inc.
What was the primary focus of HOOKIPA's research and development efforts?
HOOKIPA focused on developing immunotherapies for infectious diseases, particularly for Hepatitis B (HBV) and HIV.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: